Mezigdomide Plus Vd or Kd for RRMM
Mezigdomide Plus Vd or Kd in Relapsed/Refractory Multiple Myeloma: Updated Results From the CC-92480-MM-002 Phase I/II Trial

Released: December 12, 2024

Expiration: December 11, 2025

Activity

Progress
1
Course Completed